Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mayo clinic study to uncover how insulin deprivation affects muscle in type 1 diabetes

NCT ID NCT05985135

Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study aims to understand how insulin deprivation and high blood sugar affect protein synthesis in muscles and blood of people with type 1 diabetes. Researchers will use muscle biopsies and special amino acid labels to track protein production. The study involves 70 participants and is not testing any new treatment, but rather gathering knowledge to inform future therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Jun 2026

An estimate. Start dates often move.

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria - Type 1 Diabetes Group: \- Able to provide written consent. Exclusion Criteria - Type 1 Diabetes Group:: * BMI \< 20 or \> 32 kg/m\^2. * Celiac disease. * Pregnancy. * Smoking. * Reported history of illicit substance use. * History of active cardiovascular, cerebrovascular, or peripheral vascular disease. * Active renal disease evidenced by estimated glomerular filtration rate (GFR) \< 50 mL/min/1.73 m\^2. * Severe peripheral or autonomic neuropathy. * Dementia or any other neurologic disease. * Uncontrolled psychiatric disease. * Any learning disability. * Anemia. * Thyroid-stimulating hormone (TSH) ≥ 7 or TSH ≤ 7 and free T4 ≤ 0.9. * Hemoglobin A1c \> 9.0%. * Type 2 Diabetes Mellitus (T2DM), or impaired fasting glucose. * Detectable C peptide. Inclusion Criteria - Control Group: * Able to provide written consent. * T1DM treated with continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI) (not Degludec). Exclusion Criteria - Control Group: * BMI \< 20 or \> 32 kg/m\^2. * Celiac disease. * Pregnancy. * Smoking. * Reported history of illicit substance use. * History of active cardiovascular, cerebrovascular, or peripheral vascular disease. * Active renal disease evidenced by estimated GFR \< 50 mL/min/1.73 m\^2. * Severe peripheral or autonomic neuropathy. * Dementia or any other neurologic disease. * Uncontrolled psychiatric disease. * Any learning disability. * Anemia. * TSH ≥ 7 or TSH ≤ 7 and free T4 ≤ 0.9. * T2DM, or impaired fasting glucose.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes after total pancreatectomy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

post-surgical hypoinsulinemia type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes

Contacts and locations

Locations

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.